Highlights
- Featured Highlights Press Press ReleasesImmunomic Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ITI-3000 pDNA Vaccine for the Treatment of Merkel Cell Carcinoma -Top line data expected in second half ofRead more
BioBuzz Interview with Brian Stamper, ITI’s VP of Cell Therapy
Articles Blog Featured Highlights Presshttps://biobuzz.io/brian-stamper-appointed-vice-president-cell-therapy-operations-at-immunomic-therapeutics/Read moreImmunomic Therapeutics Appoints Vice President, Cell Therapy
Featured Highlights Press Press ReleasesJune 07, 2022 10:24 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleicRead moreITI to Participate at World Vaccine Congress Washington 2022
Featured Highlights Press Press ReleasesApril 14, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today thatRead moreITI Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at AACR 2022
Featured Highlights Press Press ReleasesBoth DNA Cancer Vaccines Studied Were Derived from Immunomic’s UNITE™ Platform Phase 1 Study of MCPyV-LT Vaccine in Merkel Cell Carcinoma to Begin in Q2 April 08, 2022 01:15 PM EasternRead moreITI Announces Two Poster Presentations at AACR Annual Meeting 2022
Featured Highlights Press Press ReleasesMarch 31, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today thatRead moreITI to present at the BIO CEO & Investor Conference 2022
Featured Highlights Press Press ReleasesFebruary 11, 2022 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced todayRead moreITI Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
Featured Highlights Press Press ReleasesFebruary 07, 2022 01:48 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein) -mediated nucleicRead moreImmunomic Therapeutics’ CBO to present at the 14th Annual Biotech Showcase Event
Featured Highlights Press ReleasesJanuary 06, 2022 12:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced todayRead more- Featured Highlights Press Press ReleasesNovember 30, 2021 02:01 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced the openingRead more
Immunomic Therapeutics Announces Collaboration With iOncologi
Featured Highlights Press Press Releases- Potential to bring in-house cell-based therapies that potentiate checkpoint inhibitors November 23, 2021 06:41 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately held clinical-stage biotechnologyRead more- Featured Highlights Press Press ReleasesNovember 18, 2021 ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (‘ITI’), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced that Kristen Batich, MD, Ph.D.Read more